Autres langues Biocon Limited

Actions

BIOCON

INE376G01013

Marché Fermé - NSE India S.E. Autres places de cotation 13:43:47 26/04/2024			Varia. 5j.	Varia. 1 janv.
306,4 ^INR	+5,06 %		+17,10 %	+22,73 %

18/04	Le laboratoire indien Biocon développe sa propre version du Wegovy, l'essai clinique devrait avoir lieu l'année prochaine	RE
17/04	Biocon Limited signe un accord exclusif de licence et de fourniture avec Biomm S.A.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

India's Biocon developing its own version of Wegovy, clinical trial likely next year	18/04
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18/04
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17/04
Biocon Board to Consider Dividend for Fiscal 2024	11/04
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	01/04
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	28/03
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	27/03
Updates On Aflibercept BPCIA Litigation	26/03
Biocon Limited Receives an Order from the Reserve Bank of India	22/03
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Biocon's CFO Resigns	15/03
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	14/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03
Biocon Limited Announces Executive Appointments	04/03
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	04/03
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara	01/03
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	29/02
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biocon Limited

Actions

BIOCON

INE376G01013

Autres langues

Filtres